Eli Lilly And Company ((LLY)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Eli Lilly and Company is spearheading a groundbreaking study titled A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes. The study aims to evaluate the effectiveness of retatrutide and tirzepatide in preventing major adverse liver outcomes in adults with high-risk metabolic dysfunction-associated steatotic liver disease (MASLD).
The study tests two drugs, retatrutide and tirzepatide, administered subcutaneously, against a placebo. These drugs are intended to mitigate the risk of significant liver complications in individuals with MASLD.
This Phase 3 trial is designed as a randomized, controlled study with a parallel intervention model. Participants will be randomly assigned to receive either the experimental drugs or a placebo, with single masking applied to participants. The primary goal is treatment-focused.
The study is set to begin recruitment on August 28, 2025, with its primary completion expected around 224 weeks later. The latest update to the study details was submitted on October 8, 2025.
The initiation of this study could potentially boost Eli Lilly’s stock performance, as successful outcomes may lead to significant advancements in liver disease treatment. Investors should watch for updates, as these could influence market dynamics, especially in comparison to competitors in the pharmaceutical industry.
The SYNERGY-OUTCOMES study is currently ongoing, with further details accessible on the ClinicalTrials portal.